Open Access
2552- https://doi.org/10.1001/jama.2020.6019
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
Translate Article 
ImportanceThe pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection.ObservationsNo proven effective therapies for this virus currently exist. The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is not US Food and Drug Administration approved and currently is being tested in ongoing randomized trials. Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended. Current clinical evidence does not support stopping angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with COVID-19.Conclusions and RelevanceThe COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918. The speed and volume of clinical trials launched to investigate potential therapies for COVID-19 highlight both the need and capability to produce high-quality evidence even in the middle of a pandemic. No therapies have been shown effective to date.
- Research Article
- 24
- 10.1053/j.gastro.2021.09.009
- Sep 8, 2021
- Gastroenterology
Targeting the Gut Microbiota in Coronavirus Disease 2019: Hype or Hope?
- Discussion
- 495
- 10.1161/jaha.120.016219
- Apr 1, 2020
- Journal of the American Heart Association
he prevalence of coronavirus disease 2019 (COVID-19) has posed a great threat to people's health worldwide, bringing a great challenges to the public healthcare systems. A recent study has confirmed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses severe acute respiratory syndrome coronavirus (SARS-CoV) receptor angiotensin-converting enzyme 2 (ACE2) for host cell entry. 1 ACE2 expression was previously found to correlate with susceptibility to SARS-CoV infection in vitro.
- Discussion
- 1
- 10.1053/j.jvca.2020.08.041
- Aug 26, 2020
- Journal of Cardiothoracic and Vascular Anesthesia
Testing the Asymptomatic Pre-Surgical Population for Severe Acute Respiratory Syndrome Coronavirus 2
- Discussion
- 2
- 10.1002/uog.23584
- Feb 1, 2021
- Ultrasound in Obstetrics & Gynecology
Scientific effort in combating COVID-19 in obstetrics and gynecology.
- Research Article
- 21
- 10.1016/j.kint.2022.07.018
- Aug 11, 2022
- Kidney International
The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases
- Research Article
- 3
- 10.1097/txd.0000000000001193
- Aug 6, 2021
- Transplantation direct
Supplemental Digital Content is available in the text.
- Discussion
- 53
- 10.1016/j.jpeds.2020.11.002
- Nov 5, 2020
- The Journal of pediatrics
Coronavirus Disease 2019 and Vaccination of Children and Adolescents: Prospects and Challenges
- Research Article
- 17
- 10.1016/j.ejim.2021.10.006
- Oct 14, 2021
- European Journal of Internal Medicine
Electrocardiographic features of patients with COVID-19: One year of unexpected manifestations
- Discussion
- 44
- 10.1161/circresaha.120.317332
- Jul 2, 2020
- Circulation Research
Response by Gheblawi et al to Letter Regarding Article, "Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2".
- Discussion
- 3
- 10.1152/japplphysiol.00775.2020
- Oct 1, 2020
- Journal of Applied Physiology
Commentaries on Viewpoint: The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies.
- Research Article
- 86
- 10.1111/ajt.16000
- Jun 11, 2020
- American Journal of Transplantation
Use of SARS-CoV-2-infected deceased organ donors: Should we always "just say no?"
- Research Article
- 5
- 10.1016/j.ajodo.2020.08.010
- Sep 21, 2020
- American Journal of Orthodontics and Dentofacial Orthopedics
COVID-19: What do we know?
- Research Article
- 95
- 10.1053/j.gastro.2020.05.009
- May 7, 2020
- Gastroenterology
SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California
- Discussion
- 25
- 10.1002/uog.24809
- Jan 13, 2022
- Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
Does COVID-19 cause pre-eclampsia?
- Research Article
- 5
- 10.1097/mcp.0000000000000771
- Mar 1, 2021
- Current Opinion in Pulmonary Medicine
Editorial: Coronavirus disease 2019 (COVID-19) - advances in epidemiology, diagnostics, treatments, host-directed therapies, pathogenesis, vaccines, and ongoing challenges.
Save Important notes in documents
Highlight text to save as a note, or write notes directly
You can also access these Documents in Paperpal, our AI writing tool
Powered by our AI Writing Assistant
